"Blood cancers, including myeloma, are the third most common form of cancer, and today new therapies are transforming the way we treat them," said Susie Novis, president and co-founder of the International Myeloma Foundation. "While the benefits from most cancer treatment are measured in months, we are seeing many of our patients experience long-term responses measured in years with new I.V. and oral medications."